美股詳情

本頁面由Tiger Fintech (Singapore) Pte. Ltd.提供服務

百濟神州

230.98

+2.841.24%

盤後：229.75-1.0150-0.44%17:21 EDT

成交量：51.99萬

成交額：1.20億

市值：248.81億

市盈率：-37.72

高：234.15

開：229.30

低：227.40

收：228.14

資料載入中...

總覽公司新聞公告

中芯國際、百濟神州：科創板牛市長期看漲

百濟神州(ONC)盤前漲超1% 公司港股被納入恒生中國企業指數成份股

恆瑞醫藥讓位“醫藥一哥”，百濟神州A股市值首度登頂

“醫藥一哥”易主！百濟神州，市值超3100億

百濟神州成A股新藥王

牛逼！百濟神州超過恆瑞了！！

百濟神州A股市值首超恆瑞醫藥業內人士：期待創新藥支持政策落實到位

每日经济新闻

歷史時刻：恆瑞退位，百濟神州加冕“A股藥王”

美股中概股盤前多數上漲，百濟神州(BGNE.O)漲超6%，嗶哩嗶哩(BILI.O)、阿里巴巴(BABA.N)漲超4%。3

百濟神州02月21日大漲，股價創歷史新高

同花顺AI资讯社

港股生物醫藥股集體走強，百濟神州(06160.HK)漲超10%

每日经济新闻

港股生物醫藥股集體走強，百濟神州(06160.HK)漲超10%，再鼎醫藥(09688.HK)漲超9%，泰格醫藥(0334

野村：維持百濟神州H股“買入”評級，目標價188.53港元

百濟神州2月18日獲南向資金加倉42.08萬股

【2月18日兩融淨買入前十：江淮汽車（2.82億元）、數據港（2.49億元）】滬深兩市數據顯示，2月18日，融資淨買入前十的股票分別為：江淮汽車（2.82億元）、數據港（2.49億元）、工商銀行（1.30億元）、中國聯通（1.24億元）、有研新材（9673.73萬元）、雲賽智聯（9048.02萬元）、正泰電器（8994.55萬元）、百濟神州（8889.86萬元）、金山辦公（8878.46萬元）、烽火通信（8679.50萬元）。

美股異動 | 獲野村積極看多百濟神州(ONC.US)盤前漲近5%

野村：維持百濟神州“買入”評級目標價上調7.8%至188.53港元

百濟神州02月18日繼續上漲，股價創歷史新高

同花顺AI资讯社

野村：維持百濟神州(06160)“買入”評級目標價上調7.8%至188.53港元

2025年有望在中國獲批的30款癌症新藥！來自恆瑞、百濟神州(06160)、阿斯利康(AZN.US)、諾華等

智通财经网

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/stock/ONC/news?page=9"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"ONC","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"ONC\",,,,,undefined,":{"symbol":"ONC","market":"US","secType":"STK","nameCN":"百濟神州","latestPrice":230.98,"timestamp":1744920000000,"preClose":228.14,"halted":0,"volume":519865,"hourTrading":{"tag":"盘后","latestPrice":229.75,"preClose":230.765,"latestTime":"17:21 EDT","volume":54100,"amount":12495855.13,"timestamp":1744924915084},"delay":0,"floatShares":79387510,"shares":107719405,"eps":-6.124009,"marketStatus":"未開盤","change":2.84,"latestTime":"04-17 16:00:00 EDT","open":229.3,"high":234.15,"low":227.3961,"amount":119885584.17555,"amplitude":0.029604,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-6.124009,"tradingStatus":0,"nextMarketStatus":{"tag":"盤前交易","tradingStatus":1,"beginTime":1745222400000},"marketStatusCode":0,"adr":0,"adrRate":13,"exchange":"NASDAQ","adjPreClose":228.14,"preHourTrading":{"tag":"盘前","latestPrice":233.81,"preClose":228.14,"latestTime":"08:41 EDT","volume":73,"amount":17065.739250000002,"timestamp":1744893686762},"postHourTrading":{"tag":"盘后","latestPrice":229.75,"preClose":230.765,"latestTime":"17:21 EDT","volume":54100,"amount":12495855.13,"timestamp":1744924915084},"volumeRatio":0.7116059393545304,"impliedVol":0.529,"impliedVolPercentile":0.8767},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"ONC\",,,,,undefined,":{"symbol":"ONC","floatShares":79387510,"roa":"-6.07%","roe":"-18.77%","lyrEps":-6.124009,"volumeRatio":0.7116059393545304,"shares":107719405,"dividePrice":0,"high":234.15,"amplitude":0.029604,"preClose":228.14,"low":227.3961,"week52Low":126.9681,"pbRate":"7.47","psRate":"6.53","week52High":287.88,"institutionHeld":0,"latestPrice":230.98,"eps":-6.124009,"divideRate":0,"volume":519865,"delay":0,"ttmEps":-6.124009,"open":229.3,"prevYearClose":184.71,"prevWeekClose":230.36,"prevMonthClose":272.17,"prevQuarterClose":272.17,"fiveDayClose":208.31,"twentyDayClose":262.59,"sixtyDayClose":222.22,"earningDate":1746547200000,"earningTime":"盘前"},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"ONC\",pageSize:20,pageCount:9,lang_content:\"cn\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2514084444","title":"中芯國際、百濟神州：科創板牛市長期看漲","url":"https://stock-news.laohu8.com/highlight/detail?id=2514084444","media":"和讯财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514084444?lang=zh_tw&edition=fundamental","pubTime":"2025-02-25 09:33","pubTimestamp":1740447180,"startTime":"0","endTime":"0","summary":"【2025 年 2 月 24 日，曾星智称“科创 50 指数”本月正式入牛市，为 A 股长期上涨力量最强指数，整体看涨科创板股票】曾星智目前持有的 2 只长线股均为科创板股票，一只是科创板市值第一，另一只是市值第四，都将坚定长期持有，股票名称为“中芯国际”“百济神州”。其表示按照“力量投资理念”作出判断，看涨科创板。需注意，以上内容仅为观点，不代表任何投资建议。\n\n\n\n海量资讯、精准解读，尽在新浪财经APP","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/roll/2025-02-25/doc-inemsfyn9163632.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["LU2148510915.USD","BK1610","BK1583","00981","LU1969619763.USD","BK4139","LU0307460666.USD","BK0239","BK1163","688235","688981","BK0214","LU0588546209.SGD","LU2328871848.SGD","159982","SGXZ49509284.SGD","BK1607","BK1500","BK1588","LU1064131003.USD","06160","SGXZ81163826.USD","BK1526","BK1161","ONC","LU1064130708.USD"],"gpt_icon":0},{"id":"2513740565","title":"百濟神州(ONC)盤前漲超1% 公司港股被納入恒生中國企業指數成份股","url":"https://stock-news.laohu8.com/highlight/detail?id=2513740565","media":"金吾财讯","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2513740565?lang=zh_tw&edition=fundamental","pubTime":"2025-02-24 19:31","pubTimestamp":1740396671,"startTime":"0","endTime":"0","summary":"金吾财讯 | 百济神州(ONC)盘前涨超1%，截至发稿，报260.04美元。消息面上，2月21日，恒生指数有限公司(恒生指数公司)宣布，截至2024年12月31日之恒生指数系列季度检讨结果，所有变动将于2025年3月7日(星期五)收市后实施并于2025年3月10日(星期一)起生效。","market":"other","thumbnail":"https://static.szfiu.com/news/20250107/M2NjYTVjM2E3MDRjYTFiZmZmYzMyZjE2M2IwN2QyMTcwMjk2NTYxMTQ=.png","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250107/M2NjYTVjM2E3MDRjYTFiZmZmYzMyZjE2M2IwN2QyMTcwMjk2NTYxMTQ=.png"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"285721","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["HSCEI","06160","LU1969619763.USD","YANG","BK1500","LU2328871848.SGD","LU0588546209.SGD","LU0307460666.USD","BK0239","BK1161","688235","ONC","BK4139","BK1583","BK1588","HSTECH"],"gpt_icon":0},{"id":"2513800718","title":"恆瑞醫藥讓位“醫藥一哥”，百濟神州A股市值首度登頂","url":"https://stock-news.laohu8.com/highlight/detail?id=2513800718","media":"财中社","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2513800718?lang=zh_tw&edition=fundamental","pubTime":"2025-02-24 14:10","pubTimestamp":1740377417,"startTime":"0","endTime":"0","summary":"2月21日，A股医药板块迎来历史性转折——以收盘价计，百济神州（688235）以3107亿元市值超越恒瑞医药（600276）的3080亿元，以27亿元的微弱优势首次登顶A股制药企业市值榜首，颠覆了恒瑞医药长期以来的“医药一哥”地位。但是，行情瞬息万变，2月24日，截至发稿，百济神州A股市值3035亿元，恒瑞医药市值3040亿元，恒瑞医药暂时领先。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202502243327630365.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["09939","BK1515","LU0588546209.SGD","06160","LU1969619763.USD","BK1500","BK4139","ONC","LU0307460666.USD","BK1161","BK1583","BK1574","LU2328871848.SGD","BK1588"],"gpt_icon":0},{"id":"2513513764","title":"“醫藥一哥”易主！百濟神州，市值超3100億","url":"https://stock-news.laohu8.com/highlight/detail?id=2513513764","media":"侃见财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2513513764?lang=zh_tw&edition=fundamental","pubTime":"2025-02-24 08:28","pubTimestamp":1740356893,"startTime":"0","endTime":"0","summary":"百济神州，迎来历史性时刻。近期，百济神州A股市值突破3107亿，其以27亿元的微弱优势超越传统巨头恒瑞医药，晋升为新的“医药一哥”。据财报显示，2021年至2023年期间，百济神州分别亏损97.48亿、136.4亿和67.16亿，三年累计亏损达301.04亿元。成为“医药一哥”百济神州崛起的背后，是一部中国创新药企打破行业桎梏的进化史。2021年至2023年，百济神州的期末现金及现金等价物余额分别为258.75亿元、201.11亿元、150.38亿元，2024年3季度末已继续下滑至121.80亿元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250224083237abda2685&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250224083237abda2685&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU2328871848.SGD","09939","LU0307460666.USD","ONC","BK1515","BK1500","LU0588546209.SGD","BK1588","BK1574","BK1583","06160","LU1969619763.USD","688235","BK1161"],"gpt_icon":0},{"id":"2513759758","title":"百濟神州成A股新藥王","url":"https://stock-news.laohu8.com/highlight/detail?id=2513759758","media":"北京商报","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2513759758?lang=zh_tw&edition=fundamental","pubTime":"2025-02-23 23:41","pubTimestamp":1740325270,"startTime":"0","endTime":"0","summary":"近期，百济神州股价持续上涨，屡创历史新高。截至收盘，百济神州总市值为3107亿元，超越恒瑞医药，跃升成为A股总市值第一的制药企业。相比恒瑞医药，百济神州的创新药率先在海外获批上市。百济神州高昂的研发费用令市场瞩目，A股上市以来，公司研发费用逐年上升，并于2022年突破百亿大关。东方财富Choice数据显示，2024年前三季度，百济神州销售费用在A股药企中排在第三位，仅次于上海医药及复星医药。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250224004915a250d614&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250224004915a250d614&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["ONC","06160","159982","399300","688235","BK0239"],"gpt_icon":0},{"id":"2513773796","title":"牛逼！百濟神州超過恆瑞了！！","url":"https://stock-news.laohu8.com/highlight/detail?id=2513773796","media":"医药之梯","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2513773796?lang=zh_tw&edition=fundamental","pubTime":"2025-02-23 20:00","pubTimestamp":1740312000,"startTime":"0","endTime":"0","summary":"百济神州的国际化布局是其市值增长的另一大动力。从投资角度来看，百济神州和恒瑞医药各有优势。在这个过程中，百济神州和恒瑞医药都将面临新的机遇和挑战，随着更多创新药企的崛起，中国医药行业的格局将更加多元化和国际化来源 |药智网","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/roll/2025-02-23/doc-inemnqyk1805814.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK1500","06160","LU0307460666.USD","LU0588546209.SGD","ONC","BK0239","BK1588","BK1583","LU1969619763.USD","BK4139","BK1161","LU2328871848.SGD","688235"],"gpt_icon":0},{"id":"2513853208","title":"百濟神州A股市值首超恆瑞醫藥 業內人士：期待創新藥支持政策落實到位","url":"https://stock-news.laohu8.com/highlight/detail?id=2513853208","media":"每日经济新闻","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2513853208?lang=zh_tw&edition=fundamental","pubTime":"2025-02-23 00:06","pubTimestamp":1740240414,"startTime":"0","endTime":"0","summary":"2月21日，A股创新药板块集体大涨，医药“老大哥”恒瑞医药被百济神州“踢馆”，首度跌下市值第一王座。当天，百济神州A股股价的涨幅是8.21%，恒瑞医药A股股价涨幅是3.83%，二者收盘市值分别为3107亿元和3080亿元，百济神州以27亿元的差距领先。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202502233326788562.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202502233326788562.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["LU0307460666.USD","LU1969619763.USD","BK1574","ONC","BK1500","BK4139","BK1161","BK1588","LU0588546209.SGD","LU2328871848.SGD","BK1583","06978","06160"],"gpt_icon":0},{"id":"2513272699","title":"歷史時刻：恆瑞退位，百濟神州加冕“A股藥王”","url":"https://stock-news.laohu8.com/highlight/detail?id=2513272699","media":"市场资讯","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2513272699?lang=zh_tw&edition=fundamental","pubTime":"2025-02-22 21:36","pubTimestamp":1740231360,"startTime":"0","endTime":"0","summary":"　　2025年2月21日下午15点，A股收盘，恒瑞医药的市值停在3080亿人民币。　　多年以来，一直有“医药一哥”之称的恒瑞医药，终于失去A股制药类企业市值第一的王座，而迅速崛起的百济神州，正式加冕“A股药王”。　　不是恒瑞不给力，只是百济神州在创新药领域显然更为优秀。　　但是即使恒瑞医药2026年这个创新药销售的业绩目标得以实现，也只是和百济神州2024年的创新药销售收入大致相当。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/stockzmt/2025-02-22/doc-inemkmzf2053518.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["06160","399300","159982","LU0588546209.SGD","ONC","688235","BK1500","BK1588","LU1969619763.USD","LU2328871848.SGD","LU0307460666.USD","BK1583","BK1161","BK4139","BK0239"],"gpt_icon":0},{"id":"2513251186","title":"美股中概股盤前多數上漲，百濟神州(BGNE.O)漲超6%，嗶哩嗶哩(BILI.O)、阿里巴巴(BABA.N)漲超4%。3","url":"https://stock-news.laohu8.com/highlight/detail?id=2513251186","media":"美港电讯","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2513251186?lang=zh_tw&edition=fundamental","pubTime":"2025-02-21 17:08","pubTimestamp":1740128882,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"2c91e638b25d0f47bf150fafe4b2b915","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.ushknews.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_meigang","symbols":["LU2226246903.HKD","IE00BFMHRM44.USD","LU1823568750.SGD","BK4122","09626","LU0348816934.USD","BK1583","LU2097828805.USD","LU1969619763.USD","LU0052756011.USD","BK4139","LU2097828557.USD","BABA","688235","BK4588","BK4527","SG9999003461.SGD","IE0034224299.USD","TTTN","LU0797268264.HKD","SG9999006597.SGD","BK4548","BK4535","BK4085","LU0310800965.SGD","BK4538","BK1588","BK4563","BK4077","06160","BK1104","BK4510","BK4607","BK4502","LU1880383366.USD","LU2097828631.EUR","09988","BK4550","BILI","LU0128525689.USD","BK4526","IE00B0JY6N72.USD","ONC","LU0918141705.HKD","BK4558","LU1152091168.USD","FDN","SG9999001051.SGD","LU0821914370.USD","LU0072913022.USD"],"gpt_icon":0},{"id":"2513225587","title":"百濟神州02月21日大漲，股價創歷史新高","url":"https://stock-news.laohu8.com/highlight/detail?id=2513225587","media":"同花顺AI资讯社","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2513225587?lang=zh_tw&edition=fundamental","pubTime":"2025-02-21 16:01","pubTimestamp":1740124883,"startTime":"0","endTime":"0","summary":"02月21日，百济神州股价大涨。截至今日收盘，百济神州上涨8.21%，收盘价为224.00元，收盘价创历史新高。百济神州有限公司是一家全球性、商业阶段的生物科技公司，专注于研究、开发、生产以及商业化创新型药物，主要产品百悦泽（（BRUKINSA），BTK抑制剂）、百泽安（抗PD-1单抗）、帕米帕利。近一年公司股价累计上涨90.88%，同期沪深300指数上涨15.09%。根据同花顺问财数据回测分析，前天出现创历史新高的股票，昨天开盘买入平均溢价为2.62%，昨天上涨概率为58.14%；昨天出现创历史新高的股票，今天开盘买入平均溢价为4.55%，今天上涨概率为77.78%。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250221160619abd7437a&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250221160619abd7437a&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["ONC","BK4139","688235","06160"],"gpt_icon":0},{"id":"2513539082","title":"港股生物醫藥股集體走強，百濟神州(06160.HK)漲超10%","url":"https://stock-news.laohu8.com/highlight/detail?id=2513539082","media":"每日经济新闻","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2513539082?lang=zh_tw&edition=fundamental","pubTime":"2025-02-21 15:36","pubTimestamp":1740123398,"startTime":"0","endTime":"0","summary":"每经AI快讯，2月21日，港股生物医药股集体走强，百济神州(06160.HK)涨超10%，再鼎医药(09688.HK)涨超9%，泰格医药(03347.HK)涨超8%，药明生物(02269.HK)涨超6%，药明康德(02359.HK)、荣昌生物(09995.HK)涨超5%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://stock.eastmoney.com/a/202502213326104570.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://stock.eastmoney.com/a/202502213326104570.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK1500","HSTECH","HSCEI","BK4139","YANG","LU0307460666.USD","BK1588","ONC","06160","BK1583","LU2328871848.SGD","LU1969619763.USD","BK1161","LU0588546209.SGD"],"gpt_icon":0},{"id":"2513605230","title":"港股生物醫藥股集體走強，百濟神州(06160.HK)漲超10%，再鼎醫藥(09688.HK)漲超9%，泰格醫藥(0334","url":"https://stock-news.laohu8.com/highlight/detail?id=2513605230","media":"美港电讯","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2513605230?lang=zh_tw&edition=fundamental","pubTime":"2025-02-21 15:32","pubTimestamp":1740123156,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.ushknews.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_meigang","symbols":["BK0239","02269","HSTECH","LU0979878070.USD","LU2488822045.USD","BK4531","LU1688375341.USD","688235","LU0320764599.SGD","161726","LU1969619763.USD","ONC","07226","03347","688331","LU1046422090.SGD","BK4585","LU1064131003.USD","02359","BK1574","LU2328871848.SGD","BK4526","BK1500","BK4588","LU0181495838.USD","LU2242644610.SGD","IE00B0JY6N72.USD","06160","LU0327786744.USD","LU0359202008.SGD","LU0588546209.SGD","BK1589","YANG","09688","LU1720050803.USD","603259","399441","ZLAB","300347","HSCEI","LU0856984785.SGD","09995","LU1064130708.USD","LU0516423174.USD","LU0516422952.EUR","LU0823426480.USD","BK0028","LU0359201612.USD","LU2045819591.USD"],"gpt_icon":0},{"id":"2512146949","title":"野村：維持百濟神州H股“買入”評級，目標價188.53港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2512146949","media":"财中社","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2512146949?lang=zh_tw&edition=fundamental","pubTime":"2025-02-19 10:42","pubTimestamp":1739932920,"startTime":"0","endTime":"0","summary":"野村近日发布报告称，维持百济神州港股“买入”评级，基于DFC估值，将目标价上调7.8%，由174.91港元升至188.53港元，认为其仍有32%的股价上升空间。野村预计百济神州2024年第4季表现强劲，2025年实现管理层指引的营运盈亏平衡。此外，野村预计百济神州在第4季录得销售额10.22亿美元及净亏损6300万美元。2024年前三季度，百济神州实现营业收入191.4亿元，同比增长48.6%，净利润亏损36.87亿元，上年同期亏损38.8亿元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250219104311988a8d5a&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250219104311988a8d5a&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["ONC"],"gpt_icon":0},{"id":"2512148944","title":"百濟神州2月18日獲南向資金加倉42.08萬股","url":"https://stock-news.laohu8.com/highlight/detail?id=2512148944","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2512148944?lang=zh_tw&edition=fundamental","pubTime":"2025-02-19 09:30","pubTimestamp":1739928626,"startTime":"0","endTime":"0","summary":"2月18日, 南向资金增持百济神州42.08万股。截止当日收盘，港股通共持有百济神州6927.26万股，占流通股4.98%。百济神州近5个交易日上涨9.06%，港股通累计增持22.42万股；近20个交易日上涨20.02%，港股通累计减持105.75万股。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250219093304a24b36d3&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250219093304a24b36d3&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK0239","688235","06160","ONC"],"gpt_icon":0},{"id":"2512120531","title":"【2月18日兩融淨買入前十：江淮汽車（2.82億元）、數據港（2.49億元）】滬深兩市數據顯示，2月18日，融資淨買入前十的股票分別為：江淮汽車（2.82億元）、數據港（2.49億元）、工商銀行（1.30億元）、中國聯通（1.24億元）、有研新材（9673.73萬元）、雲賽智聯（9048.02萬元）、正泰電器（8994.55萬元）、百濟神州（8889.86萬元）、金山辦公（8878.46萬元）、烽火通信（8679.50萬元）。","url":"https://stock-news.laohu8.com/highlight/detail?id=2512120531","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2512120531?lang=zh_tw&edition=fundamental","pubTime":"2025-02-19 08:49","pubTimestamp":1739926194,"startTime":"0","endTime":"0","summary":"沪深两市数据显示，2月18日，融资净买入前十的股票分别为：江淮汽车（2.82亿元）、数据港（2.49亿元）、工商银行（1.30亿元）、中国联通（1.24亿元）、有研新材（9673.73万元）、云赛智联（9048.02万元）、正泰电器（8994.55万元）、百济神州（8889.86万元）、金山办公（8878.46万元）、烽火通信（8679.50万元）。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://24h.jrj.com.cn/2025/02/19084948245387.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["BK0175","600602","BK1506","BK4526","BK4608","CHU","IE00BVYPNP33.GBP","LU1064131003.USD","ONC","LU1794554557.SGD","BK0224","BK4139","LU1481107354.HKD","LU1720050803.USD","688235","LU1969619763.USD","399300","BK0196","01398","600418","BK0201","600498","BK0125","LU0164880469.USD","LU0164865239.USD","688111","LU0405327148.USD","00762","159982","06160","BK1583","600050","BK0084","SG9999001069.SGD","LU0871576103.HKD","LU0181495838.USD","BK0030","LU1064130708.USD","BK1560","601877","600206","LU0051755006.USD","BK1521","601398","SG9999006597.SGD","BK0006","603881","03143","SG9999001093.SGD"],"gpt_icon":0},{"id":"2512633961","title":"美股異動 | 獲野村積極看多 百濟神州(ONC.US)盤前漲近5%","url":"https://stock-news.laohu8.com/highlight/detail?id=2512633961","media":"智通财经","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2512633961?lang=zh_tw&edition=fundamental","pubTime":"2025-02-18 22:20","pubTimestamp":1739888403,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，周二，百济神州(ONC.US)美股盘前涨近5%，报242.25美元。野村发布报告称，维持百济神州“买入”评级，基于DFC估值，将目标价上调7.8%，由174.91港元升至188.53港元，认为其仍有32%的股价上升空间。野村预计百济神州2024年第4季表现强劲，2025年实现管理层指引的营运盈亏平衡。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1251365.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["ONC","BK4139","BK1500","BK1588","LU0588546209.SGD","688235","BK1583","LU0307460666.USD","BK0239","LU2328871848.SGD","BK1161","LU1969619763.USD","06160"],"gpt_icon":0},{"id":"2512134004","title":"野村：維持百濟神州“買入”評級 目標價上調7.8%至188.53港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2512134004","media":"新浪港股","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2512134004?lang=zh_tw&edition=fundamental","pubTime":"2025-02-18 17:40","pubTimestamp":1739871600,"startTime":"0","endTime":"0","summary":"　　野村发布报告称，维持百济神州“买入”评级，基于DFC估值，将目标价上调7.8%，由174.91港元升至188.53港元，认为其仍有32%的股价上升空间。野村预计百济神州2024年第4季表现强劲，2025年实现管理层指引的营运盈亏平衡。　　野村称，由于Zanubrutinib销售预测上调，上调2024及2025年收入预测分别至37亿美元及47亿美元。考虑到加速折旧导致毛利率下降，上调2024年净亏损，但又因销售预估上调带来更大的规模经济效益，故下调2025年净亏损。","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/hkstock/hkgg/2025-02-18/doc-inekwyzc5775049.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["688235","06160","ONC"],"gpt_icon":0},{"id":"2512087135","title":"百濟神州02月18日繼續上漲，股價創歷史新高","url":"https://stock-news.laohu8.com/highlight/detail?id=2512087135","media":"同花顺AI资讯社","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2512087135?lang=zh_tw&edition=fundamental","pubTime":"2025-02-18 16:15","pubTimestamp":1739866548,"startTime":"0","endTime":"0","summary":"02月18日，百济神州股价继续上涨。截至今日收盘，百济神州上涨2.20%，收盘价为205.98元，盘中股价最高触及210.00元，股价创历史新高。百济神州有限公司是一家全球性、商业阶段的生物科技公司，专注于研究、开发、生产以及商业化创新型药物，主要产品百悦泽、百泽安、帕米帕利。近一年公司股价累计上涨78.46%，同期沪深300指数上涨16.28%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250218162803a24a4990&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250218162803a24a4990&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["06160","688235","BK0239","ONC"],"gpt_icon":0},{"id":"2512135283","title":"野村：維持百濟神州(06160)“買入”評級 目標價上調7.8%至188.53港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2512135283","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2512135283?lang=zh_tw&edition=fundamental","pubTime":"2025-02-18 16:13","pubTimestamp":1739866431,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，野村发布报告称，维持百济神州(06160)“买入”评级，基于DFC估值，将目标价上调7.8%，由174.91港元升至188.53港元，认为其仍有32%的股价上升空间。野村预计百济神州2024年第4季表现强劲，2025年实现管理层指引的营运盈亏平衡。野村称，由于Zanubrutinib(BTK抑制剂)销售预测上调，上调2024及2025年收入预测分别至37亿美元及47亿美元。考虑到加速折旧导致毛利率下降，上调2024年净亏损，但又因销售预估上调带来更大的规模经济效益，故下调2025年净亏损。此外，野村预计百济神州在第4季录得销售额10.22亿美元及净亏损6300万美元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1251103.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["688235","ONC","06160"],"gpt_icon":0},{"id":"2512902244","title":"2025年有望在中國獲批的30款癌症新藥！來自恆瑞、百濟神州(06160)、阿斯利康(AZN.US)、諾華等","url":"https://stock-news.laohu8.com/highlight/detail?id=2512902244","media":"智通财经网","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2512902244?lang=zh_tw&edition=fundamental","pubTime":"2025-02-18 11:10","pubTimestamp":1739848232,"startTime":"0","endTime":"0","summary":"2025年有望在中国获批上市的30款癌症领域新药，它们有望为肺癌、乳腺癌、卵巢癌、前列腺癌、鼻咽癌、胃癌、结直肠癌、淋巴瘤、白血病等一系列癌症类型带来新的治疗选择。","market":"sh","thumbnail":"https://img.zhitongcaijing.com/image/20250218/20250218104841_74202.png?x-oss-process=image/format,jpg/quality,Q_80/resize,w_250","type":0,"news_type":0,"thumbnails":["https://img.zhitongcaijing.com/image/20250218/20250218104841_74202.png?x-oss-process=image/format,jpg/quality,Q_80/resize,w_250"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1250995.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"highlight_zhitongcaijin","symbols":["IE00BJJMRZ35.SGD","IE00BJT1NW94.SGD","BK4139","IE00BFTCPJ56.SGD","LU2328871848.SGD","IE0009355771.USD","BK4532","LU2462157665.USD","ONC","BK0239","LU0588546209.SGD","LU2456880835.USD","BK1588","IE0002141913.USD","688235","NVS","LU0211331839.USD","BK1500","LU1969619763.USD","BK1583","LU1829250122.USD","LU0109394709.USD","IE00B4R5TH58.HKD","BK4007","LU0889565916.HKD","IE00B2B36J28.USD","BK4578","LU2417539215.USD","LU2236285917.USD","BK4585","06160","BK1161","LU0307460666.USD","BK4588","LU0320765992.SGD","BK4568","AZN"],"gpt_icon":1}],"pageSize":20,"totalPage":10,"pageCount":9,"totalSize":200,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/ONC\",params:#limit:5,,,undefined,":[{"date":"2025-05-07","symbol":"ONC","type":"earning","reportTimeType":"pre","market":"US","fiscalQuarterEnding":"2025/03","expectedEps":-0.74,"defaultRemindTime":1746604800000,"name":null,"time":"盤前","dateTimestamp":1746590400000,"actualEps":null},{"market":"US","date":"2025-02-27","symbol":"ONC","fiscalQuarterEnding":"2024/12","expectedEps":-0.88,"name":null,"time":"盤前","type":"earning","dateTimestamp":1740632400000,"reportTimeType":"pre","actualEps":-1.43},{"market":"US","date":"2024-11-12","symbol":"ONC","fiscalQuarterEnding":"2024/09","expectedEps":-0.88,"name":null,"time":"盤前","type":"earning","dateTimestamp":1731387600000,"reportTimeType":"pre","actualEps":-1.15},{"market":"US","date":"2024-08-07","symbol":"ONC","fiscalQuarterEnding":"2024/06","expectedEps":-2.1,"name":null,"time":"盤前","type":"earning","dateTimestamp":1723003200000,"reportTimeType":"pre","actualEps":-1.15},{"market":"US","date":"2024-05-11","symbol":"ONC","fiscalQuarterEnding":null,"expectedEps":null,"name":null,"time":"盤後","type":"earning","dateTimestamp":1715400000000,"reportTimeType":"post","actualEps":null}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"ONC\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"ONC\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0.2727,"buy":0.6818,"hold":0.0455,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":0.6818,"analysts":22,"updateTime":1744084800000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/ONC\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"ONC","date":"2025-04-17","current":-38.113584,"percent":0.422535,"low":-46.072488,"twenty":-42.748137,"median":-33.549429,"eighty":-28.784295,"high":-22.805663,"avg":-34.842528,"sd":7.324243,"marketCap":24575105056},"quantilePoints":[{"date":"2025-01-03","current":-23.85925,"twenty":-23.85925,"median":-23.85925,"eighty":-23.85925,"marketCap":19590153584},{"date":"2025-01-10","current":-23.169003,"twenty":-23.588216,"median":-23.51181,"eighty":-23.096335,"marketCap":18938568040},{"date":"2025-01-17","current":-26.770744,"twenty":-26.217794,"median":-23.689854,"eighty":-23.142836,"marketCap":21882666138},{"date":"2025-01-24","current":-28.798988,"twenty":-27.60701,"median":-25.13119,"eighty":-23.374687,"marketCap":23683664763},{"date":"2025-01-31","current":-29.253094,"twenty":-28.895055,"median":-26.770744,"eighty":-23.516999,"marketCap":24179205805},{"date":"2025-02-07","current":-29.699946,"twenty":-29.114029,"median":-28.456686,"eighty":-23.723733,"marketCap":24422582437},{"date":"2025-02-14","current":-29.279798,"twenty":-29.132261,"median":-28.781271,"eighty":-23.9826,"marketCap":24061904635},{"date":"2025-02-21","current":-31.546239,"twenty":-29.269116,"median":-28.798062,"eighty":-24.917918,"marketCap":26058437677},{"date":"2025-02-28","current":-46.072488,"twenty":-30.312806,"median":-28.916244,"eighty":-26.238043,"marketCap":29706894943},{"date":"2025-03-07","current":-42.702936,"twenty":-33.205878,"median":-29.060335,"eighty":-26.487572,"marketCap":27534255325},{"date":"2025-03-14","current":-42.304107,"twenty":-40.627279,"median":-29.228112,"eighty":-26.926934,"marketCap":27277096074},{"date":"2025-03-21","current":-43.63686,"twenty":-41.989697,"median":-29.279798,"eighty":-27.60701,"marketCap":28136436571},{"date":"2025-03-28","current":-43.795471,"twenty":-42.273573,"median":-29.808923,"eighty":-28.393975,"marketCap":28238706493},{"date":"2025-04-04","current":-44.082326,"twenty":-43.290212,"median":-30.877376,"eighty":-28.597906,"marketCap":28423666794},{"date":"2025-04-11","current":-34.741183,"twenty":-42.946887,"median":-33.164233,"eighty":-28.695114,"marketCap":22400628140},{"date":"2025-04-17","current":-38.113584,"twenty":-42.748137,"median":-33.549429,"eighty":-28.784295,"marketCap":24575105056}],"updateTime":1745185820091}}}